Atlas Trials

Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML

Clinical trial NCT05982756 · UNKNOWN

Trial details

NCT number
NCT05982756
Sponsor
Zhongnan Hospital
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
BortezomibAcute Myeloid Leukemia
Start date
2020-01-01
Primary completion
2023-09-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.